Dr. Dorff on Incorporating mCRPC Prognostic Models Into Clinical Practice

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center, explains the challenges of providing useful and accurate prognostic information to patients with mCRPC, how the prognostic model from the CALGB 90401 trial may alleviate some of those issues, and what needs to happen to move the model into standard practice.

Her comments are in relation to her recent editorial in the Journal of Clinical Oncology, “Incorporating Prognostic Models Into Clinical Practice for Patients With Castration-Resistant Prostate Cancer.”